Sachin B Baravkar, Yan Lu, Qi Zhao, Hongying Peng, Weilie Zhou, Song Hong
{"title":"合理设计的Aβ19-23片段五肽类似物作为Aβ42聚集的有效抑制剂。","authors":"Sachin B Baravkar, Yan Lu, Qi Zhao, Hongying Peng, Weilie Zhou, Song Hong","doi":"10.3390/molecules30092071","DOIUrl":null,"url":null,"abstract":"<p><p>Amyloid beta (Aβ42 and Aβ40) aggregation, along with neurofibrillary tangles, is one of the major neurotoxic events responsible for the onset of Alzheimer's disease. Many potent peptide-based inhibitors mainly focusing on central hydrophobic core Aβ16-20 (KLVFF) have been reported in recent years. Herein, we report pentapeptides <b>1</b>-<b>4</b>, based on the β-turn-inducing fragment Aβ19-23 (FFAED). The synthesis of peptides <b>1</b>-<b>4</b> was carried out using Fmoc/tBu-based solid-phase peptide synthesis technique, and it was found that pentapeptide <b>3</b> potently inhibit the aggregation propensity of Aβ42, when incubated with it at 37 °C for 48 h. The aggregation inhibition study was conducted using thioflavin T-based fluorescence assay and circular dichroism spectroscopy, and supported by transmission electron microscope imaging. The conformational change on the aggregation of Aβ42 and aggregation inhibition by peptides <b>1</b>-<b>4</b> was further evaluated using <sup>1</sup>H-<sup>15</sup>N HSQC NMR spectroscopy. The results demonstrated that the most potent analog, peptide <b>3</b>, effectively disrupts the aggregation process. This study is the first to demonstrate that an Aβ19-23 fragment mimic can disrupt the aggregation propensity of Aβ42.</p>","PeriodicalId":19041,"journal":{"name":"Molecules","volume":"30 9","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12073614/pdf/","citationCount":"0","resultStr":"{\"title\":\"Rationally Designed Pentapeptide Analogs of Aβ19-23 Fragment as Potent Inhibitors of Aβ42 Aggregation.\",\"authors\":\"Sachin B Baravkar, Yan Lu, Qi Zhao, Hongying Peng, Weilie Zhou, Song Hong\",\"doi\":\"10.3390/molecules30092071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Amyloid beta (Aβ42 and Aβ40) aggregation, along with neurofibrillary tangles, is one of the major neurotoxic events responsible for the onset of Alzheimer's disease. Many potent peptide-based inhibitors mainly focusing on central hydrophobic core Aβ16-20 (KLVFF) have been reported in recent years. Herein, we report pentapeptides <b>1</b>-<b>4</b>, based on the β-turn-inducing fragment Aβ19-23 (FFAED). The synthesis of peptides <b>1</b>-<b>4</b> was carried out using Fmoc/tBu-based solid-phase peptide synthesis technique, and it was found that pentapeptide <b>3</b> potently inhibit the aggregation propensity of Aβ42, when incubated with it at 37 °C for 48 h. The aggregation inhibition study was conducted using thioflavin T-based fluorescence assay and circular dichroism spectroscopy, and supported by transmission electron microscope imaging. The conformational change on the aggregation of Aβ42 and aggregation inhibition by peptides <b>1</b>-<b>4</b> was further evaluated using <sup>1</sup>H-<sup>15</sup>N HSQC NMR spectroscopy. The results demonstrated that the most potent analog, peptide <b>3</b>, effectively disrupts the aggregation process. This study is the first to demonstrate that an Aβ19-23 fragment mimic can disrupt the aggregation propensity of Aβ42.</p>\",\"PeriodicalId\":19041,\"journal\":{\"name\":\"Molecules\",\"volume\":\"30 9\",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12073614/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecules\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.3390/molecules30092071\",\"RegionNum\":2,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecules","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.3390/molecules30092071","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Rationally Designed Pentapeptide Analogs of Aβ19-23 Fragment as Potent Inhibitors of Aβ42 Aggregation.
Amyloid beta (Aβ42 and Aβ40) aggregation, along with neurofibrillary tangles, is one of the major neurotoxic events responsible for the onset of Alzheimer's disease. Many potent peptide-based inhibitors mainly focusing on central hydrophobic core Aβ16-20 (KLVFF) have been reported in recent years. Herein, we report pentapeptides 1-4, based on the β-turn-inducing fragment Aβ19-23 (FFAED). The synthesis of peptides 1-4 was carried out using Fmoc/tBu-based solid-phase peptide synthesis technique, and it was found that pentapeptide 3 potently inhibit the aggregation propensity of Aβ42, when incubated with it at 37 °C for 48 h. The aggregation inhibition study was conducted using thioflavin T-based fluorescence assay and circular dichroism spectroscopy, and supported by transmission electron microscope imaging. The conformational change on the aggregation of Aβ42 and aggregation inhibition by peptides 1-4 was further evaluated using 1H-15N HSQC NMR spectroscopy. The results demonstrated that the most potent analog, peptide 3, effectively disrupts the aggregation process. This study is the first to demonstrate that an Aβ19-23 fragment mimic can disrupt the aggregation propensity of Aβ42.
期刊介绍:
Molecules (ISSN 1420-3049, CODEN: MOLEFW) is an open access journal of synthetic organic chemistry and natural product chemistry. All articles are peer-reviewed and published continously upon acceptance. Molecules is published by MDPI, Basel, Switzerland. Our aim is to encourage chemists to publish as much as possible their experimental detail, particularly synthetic procedures and characterization information. There is no restriction on the length of the experimental section. In addition, availability of compound samples is published and considered as important information. Authors are encouraged to register or deposit their chemical samples through the non-profit international organization Molecular Diversity Preservation International (MDPI). Molecules has been launched in 1996 to preserve and exploit molecular diversity of both, chemical information and chemical substances.